Desensitization effect of preseasonal seven-injection allergoid immunotherapy with olive pollen on basophil activation: The efficacy of olive pollen-specific preseasonal allergoid immunotherapy on basophils

International Archives of Allergy and Immunology

Volumn 159, Issue 1, 2012, Pages 75-82

  Gokmen, Nihal Mete ^a   Ersoy, Ramazan ^a   Gulbahar, Okan ^a   Ardeniz, Omur ^a   Sin, Aytul ^a   Unsel, Mehmet ^a   Kokuludag, Ali ^a  

^a EGE UNIVERSITY   (Turkey)

Author keywords

Allergen specific immunotherapy; Allergen specific nasal challenge; Allergoid; Basophil activation test; Olea europaea pollen

Indexed keywords

CD63 ANTIGEN; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G4; POLLEN ANTIGEN;

ADOLESCENT; ADULT; ALLERGIC ASTHMA; ALLERGIC RHINITIS; ARTICLE; BASOPHIL; DESENSITIZATION; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; FLOW CYTOMETRY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; OLIVE; POLLEN; PRICK TEST; PRIORITY JOURNAL; SUBCUTANEOUS IMMUNOTHERAPY; SUBCUTANEOUS NODULE; URTICARIA;

ADOLESCENT; ADULT; ALLERGENS; BASOPHILS; DESENSITIZATION, IMMUNOLOGIC; FEMALE; HUMANS; INJECTIONS; MALE; MIDDLE AGED; NASAL PROVOCATION TESTS; OLEA; PLANT EXTRACTS; POLLEN; RESPIRATORY HYPERSENSITIVITY; SEASONS; SKIN TESTS; TIME FACTORS; YOUNG ADULT;

EID: 84860844285     PISSN: 10182438     EISSN: 14230097     Source Type: Journal    
DOI: 10.1159/000335251     Document Type: Article

References (37)

1. Bousquet J, Lockey R, Malling HJ: Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. J Allergy Clin Immunol 1998; 102: 558-562.
2. Gardner LM, Spyroglou L, O'Hehir RE, Rolland JM: Increased allergen concentration enhances IFN-gamma production by allergic donor T cells expressing a peripheral tissue trafficking phenotype. Allergy 2004; 59: 1308-1317. (Pubitemid 39506730)
3. Malling H, Weeke B: Position paper: immunotherapy. Allergy 1993; 48: 9-35. (Pubitemid 23222930)
4. Bousquet J, Demoly P: Allergens in 1998: from molecular biology to improved patient care. Allergy 1998; 53: 549-551. (Pubitemid 28307921)
5. Norman PS, Lichtenstein LM, Marsh DG: Studies on allergoids from naturally occurring allergens. IV. Efficacy and safety of long-term allergoid treatment of ragweed hay fever. J Allergy Clin Immunol 1981; 68: 460-470. (Pubitemid 12254024)
6. Negro JM, Wheeler AW, Hernández J, et al: Comparison of the efficacy and safety of two preseasonal regimens of glutaraldehyde modified, tyrosine-adsorbed parietaria pollen extract over a period of three years in monosensitive patients. Allergol Immunopathol (Madr) 1999; 27: 153-164. (Pubitemid 29336879)
7. Ariano R, Panzani RC, Mistrello G: Efficacy of sublingual coseasonal immunotherapy with a monomeric allergoid in Cupressaceae pollen allergy -preliminary data. Eur Ann Allergy Clin Immunol 2005; 37: 103-108. (Pubitemid 40515923)
8. Kahlert H, Grage-Griebenow E, Stuwe HT, Cromwell O, Fiebig H: T cell reactivity with allergoids: influence of the type of APC. J Immunol 2000; 165: 1807-1815. (Pubitemid 30643130)
9. Secrist H, DeKruyff RH, Umetsu DT: Interleukin 4 production by CD4+ T cells from allergic individuals is modulated by antigen concentration and antigen-presenting cell type. J Exp Med 1995; 181: 1081-1089.
10. Corrigan CJ, Kettner J, Doemer C, Cromwell O, Narkus A: Efficacy and safety of preseasonal-specific immunotherapy with an aluminium-adsorbed six-grass pollen allergoid. Allergy 2005; 60: 801-807. (Pubitemid 40769884)
11. Williams A, Henzgen M, Rajakulasingam K: Additional benefit of a third year of specific grass pollen allergoid immunotherapy in patients with seasonal allergic rhinitis. Eur Ann Allergy Clin Immunol 2007; 39: 123-126. (Pubitemid 46732364)
12. Riechelmann H, Schmutzhard J, van der Werf JF, Distler A, Kleinjans HA: Efficacy and safety of a glutaraldehyde-modified house dust mite extract in allergic rhinitis. Am J Rhinol Allergy 2010; 24:e104-e109.
13. Keskin O, Tuncer A, Adalioglu G, Sekerel BE, Sackesen C, Kalayci O: The effects of grass pollen allergoid immunotherapy on clinical and immunological parameters in children with allergic rhinitis. Pediatr Allergy Immunol 2006; 17: 396-407. (Pubitemid 44289468)
14. Palma-Carlos AG, Santos AS, Branco-Ferreira M, et al: Clinical efficacy and safety of preseasonal sublingual immunotherapy with grass pollen carbamylated allergoid in rhinitic patients. A double-blind, placebocontrolled study. Allergol Immunopathol 2006; 34: 194-198. (Pubitemid 44875056)
15. Pacor ML, Biasi D, Carletto A, Maleknia T, Lunardi C: Oral immunotherapy in oculorhinitis from Gramineae (in Italian). Recenti Prog Med 1996; 87: 4-6. (Pubitemid 26116277)
16. Caffarelli C, Sensi LG, Marcucci F, Cavagni G: Preseasonal local allergoid immunotherapy to grass pollen in children: a doubleblind, placebo-controlled, randomized trial. Allergy 2000; 55: 1142-1147.
17. Passali D, Mösges R, Passali GC, Passali FM, Ayoko G, Bellussi L: Safety, tolerability and efficacy of sublingual allergoid immunotherapy with three different shortened updosing administration schedules. Acta Otorhinolaryngol Ital 2010; 30: 131-137.
18. Klimek L, Dormann D, Jarman ER, Cromwell O, Riechelmann H, Reske-Kunz AB: Short-term preseasonal birch pollen allergoid immunotherapy influences symptoms, specific nasal provocation and cytokine levels in nasal secretions, but not peripheral Tcell responses, in patients with allergic rhinitis. Clin Exp Allergy 1999; 29: 1326-1335. (Pubitemid 29467956)
19. Zafer Can H, Isfendiyaroglu M: Olive oil sector in Turkey; in Caruso T, Motisi A, Sebastiani L (eds): Recent Advances in Olive Industry. Special Seminars and Invited Lectures. OliveBioteq. Napoli, 2006, pp 109-119.
20. Bachert C, van Cauwenberge P, Khaltaev N, World Health Organization: Allergic rhinitis and its impact on asthma. In collaboration with the World Health Organization. Executive summary of the workshop report. 7-10 December 1999, Geneva, Switzerland. Allergy 2002; 57: 841-855.
21. Abaylica E, Ay G, Urk V, Yuksel H: Aeropalynological pollen count in Akhisar region of Manisa, Turkey. III. Istanbul, Balkan Congress of Allergy and Clinical Immunology, 2003, abstract book, p 109.
22. Food and Drug Administration. Center for Drug Evaluation and Research: Allergic Rhinitis: Clinical Development Programs for Drug Products. Guidance for Industry. http://www.fda.gov/cder/guidance/index. htm
23. Alvarez-Cuesta E, Bousquet J, Canonica GW, Durham SR, Malling HJ, Valovirta E, EAACI, Immunotherapy Task Force: Standards for practical allergen-specific immunotherapy. Allergy 2006; 61(suppl 82):1-20.
24. Akerlund A, Andersson M, Leflein J, Lildholdt T, Mygind N: Clinical trial design, nasal allergen challenge models, and considerations of relevance to pediatrics, nasal polyposis, and different classes of medication. J Allergy Clin Immunol 2005; 115: 460-482.
25. Fabbri A, Bartolini G, Lambardi M, Kailis S: Introduction; in Fabbri A, Bartolini G, Lambardi M, Kailis S (eds): Olive Propagation Manual. Collingwood, Landlinks, 2004, pp 1-7.
26. Anastassakis KK, Chatzimichail A, Androulakis I, et al: Skin prick test reactivity to common aeroallergens and ARIA classification of allergic rhinitis in patients of Central Greece. Eur Arch Otorhinolaryngol 2010; 267: 77-85.
27. Antonicelli L, Micucci C, Voltolini S, et al: Allergic rhinitis and asthma comorbidity: ARIA classification of rhinitis does not correlate with the prevalence of asthma. Clin Exp Allergy 2007; 37: 954-960. (Pubitemid 47074560)
28. Navarro A, Valero A, Julia B, Quirce S: Coexistence of asthma and allergic rhinitis in adult patients attending allergy clinics: ONEAIR study. J Investig Allergol Clin Immunol 2008; 18: 233-238. (Pubitemid 352031566)
29. Gioulekas D, Papakosta D, Damialis A, Spieksma F, Giouleka P, Patakas D: Allergenic pollen records (15 years) and sensitization in patients with respiratory allergy in Thessaloniki, Greece. Allergy 2004; 59: 174-184. (Pubitemid 38250773)
30. Akdis M, Akdis CA: Mechanisms of allergen-specific immunotherapy. J Allergy Clin Immunol 2007; 119: 780-791.
31. Ebo DG, Hagendorens MM, Schuerwegh AJ, et al: Flow-assisted quantification of in vitro activated basophils in the diagnosis of wasp venom allergy and follow-up of wasp venom immunotherapy. Cytometry B Clin Cytom 2007; 72: 196-203. (Pubitemid 46676752)
32. Jones SM, Pons L, Roberts JL, et al: Clinical efficacy and immune regulation with peanut oral immunotherapy. J Allergy Clin Immunol 2009; 124: 292-300.e97.
33. Lalek N, Kosnik M, Silar M, Korosec P: Immunoglobulin G-dependent changes in basophil allergen threshold sensitivity during birch pollen immunotherapy. Clin Exp Allergy 2010; 40: 1186-1193.
34. Cady CT, Powell MS, Harbeck RJ, et al: IgG antibodies produced during subcutaneous allergen immunotherapy mediate inhibition of basophil activation via a mechanism involving both Fc; RIIA and Fc; RIIB. Immunol Lett 2010; 130: 57-65.
35. Guerra F, Moreno C, Daza JC, Miguel R, Garcia M, Sanchez Guijo P: Linear monitoring of patients sensitive to Olea and grass pollens treated with immunotherapy based on glutaraldehyde-modified (allergoid) extracts. J Investig Allergol Clin Immunol 1993; 3: 182-190. (Pubitemid 23276664)
36. Pastorello EA, Pravettoni V, Incorvaia C, et al: Clinical and immunological effects of immunotherapy with alum-absorbed grass allergoid in grass-pollen-induced hay fever. Allergy 1992; 47: 281-290.
37. Brehler R, Kahlert H, Thum-Oltmer S: Hypoallergenic preparations in SCIT. Immunological features and their impact on clinical efficacy and safety, exemplary for the allergoids Allergovit Acaroid and a folding variant of the recombinant birch pollen major allergen Bet v 1. Allergo J 2010; 19: 477-484.